Biological Response Modifiers Cmte. Renamed Cellular, Tissue & Gene Therapies
This article was originally published in The Pink Sheet Daily
Responsibilities changed to more accurately reflect subject areas commonly addressed by FDA advisory committee. The committee held only one meeting in the last year, added two new members.
You may also be interested in...
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.
FDA’s Psychopharmacologic Drugs Advisory Committee rules safety for modafinil product in children with attention deficit/hyperactivity disorder has not been adequately demonstrated.